First-in-Class HEOR Challenges and Regulatory Framework Shifts

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: Baxdrostat's first-in-class HEOR challenge, Revolution Medicines' KRAS breakthrough, and Genentech's academic research strategy. Let's get into it.

SaraStarting with Baxdrostat. FDA approved it May 18 as the first aldosterone synthase inhibitor for hypertension. That's a novel mechanism in a crowded therapeutic space with established, cheap generics.

MarcusThe HEOR challenge here is demonstrating value when you're not just another ACE inhibitor. If this truly targets resistant hypertension effectively, the comparator set narrows significantly. Cost per controlled patient becomes the key metric, not cost per prescription.

SaraBut that's assuming resistant hypertension is the real-world positioning. The approval doesn't restrict it there. If this gets prescribed broadly as another antihypertensive option, you're back to competing on acquisition cost against decades-old generics.

MarcusFair point. The evidence strategy has to be laser-focused on the resistant population where existing therapies fail. Otherwise, the HEOR story falls apart completely.

SaraExactly. And payers won't differentiate mechanisms—they'll differentiate outcomes. If you can't show superior blood pressure control or reduced cardiovascular events in the population that matters, the novel mechanism becomes expensive novelty.

MarcusMoving to Revolution Medicines. They presented what they're calling "stunning results" for daraxonrasib in pancreatic cancer at ASCO. KRAS has been the holy grail target—previously undruggable.

SaraPancreatic cancer is where HEOR frameworks get stress-tested. Median survival measured in months, not years. Any meaningful extension justifies significant cost under most value frameworks.

MarcusTrue, but "stunning" is marketing language. We need to see the actual survival curves and response rates. Pancreatic cancer has seen promising early results before that didn't translate to practice-changing outcomes.

SaraThat's the perpetual optimism bias in oncology. But if this truly cracks KRAS—and they're already starting early access programs—the health economic implications extend far beyond pancreatic cancer. KRAS mutations drive multiple tumor types.

MarcusWhich raises the platform value question. Do you price for pancreatic cancer where patients are desperate, or price for the broader KRAS-mutant oncology market where you'll face more competition?

SaraThe strategy has to be sequential. Establish value in the most desperate indication first, then expand. But the HEOR models need to anticipate that expansion from day one.

MarcusNow this Genentech story is fascinating. They're offering up to $125,000 grants to academics for research on pricing policy consequences and R&D risks. That's HEOR evidence generation with a very specific agenda.

SaraIt's not subtle. They want academic credibility for positions that support their commercial interests. The question is whether the research questions are legitimate, regardless of who's funding them.

MarcusBut there's an inherent bias problem. When you're soliciting research to "blunt pharma reforms," you're not funding neutral inquiry. You're funding advocacy with academic window dressing.

SaraI disagree. The research questions around pricing policy unintended consequences are valid. If academics can maintain methodological rigor despite funding source, we get useful evidence. The funding source doesn't invalidate good research.

MarcusThat's naive, Sara. The solicitation itself shapes what gets studied and how it gets framed. When you're explicitly seeking research to support policy positions, you're corrupting the evidence base.

SaraSo who should fund research on pharmaceutical policy impacts? Government agencies with their own political biases? The questions need answering regardless of funding source politics.

MarcusFinally, EMA's annual report from March shows their focus on optimizing medicines assessments and implementing the HTA Regulation. The coordination between regulatory approval and health technology assessment is tightening.

SaraThat integration is long overdue. The artificial separation between safety-efficacy assessment and value assessment creates inefficiencies and delays patient access.

MarcusBut it also creates new risks. When regulatory and HTA processes become too aligned, you lose the independence that makes each valuable. HTA bodies need freedom to reach different conclusions than regulators.

SaraThe goal isn't identical conclusions—it's coordinated processes. Better information sharing, aligned timelines, reduced duplication. That benefits everyone.

MarcusAs long as it doesn't become regulatory capture where HTA decisions get predetermined by EMA positions.

SaraThe market access landscape keeps evolving. First-in-class approvals like Baxdrostat test our value frameworks. Industry-funded advocacy research blurs evidence boundaries.

MarcusAnd regulatory-HTA integration changes how we think about evidence strategy from the beginning. The old sequential model is dead—everything needs to be coordinated from Phase I forward.

SaraBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.